1. Home
  2. XGN vs LEXX Comparison

XGN vs LEXX Comparison

Compare XGN & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Exagen Inc.

XGN

Exagen Inc.

N/A

Current Price

$6.67

Market Cap

253.9M

Sector

Health Care

ML Signal

N/A

Logo Lexaria Bioscience Corp.

LEXX

Lexaria Bioscience Corp.

HOLD

Current Price

$0.67

Market Cap

14.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XGN
LEXX
Founded
2002
2004
Country
United States
Canada
Employees
N/A
7
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
253.9M
14.5M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
XGN
LEXX
Price
$6.67
$0.67
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
1
Target Price
$13.67
$4.00
AVG Volume (30 Days)
246.3K
366.8K
Earning Date
11-04-2025
01-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$63,599,000.00
$705,923.00
Revenue This Year
$22.15
$13.35
Revenue Next Year
$15.26
$78.83
P/E Ratio
N/A
N/A
Revenue Growth
14.08
52.05
52 Week Low
$2.67
$0.48
52 Week High
$12.23
$2.43

Technical Indicators

Market Signals
Indicator
XGN
LEXX
Relative Strength Index (RSI) 32.41 34.53
Support Level $6.37 $0.48
Resistance Level $7.29 $1.44
Average True Range (ATR) 0.35 0.12
MACD 0.05 -0.06
Stochastic Oscillator 35.48 19.53

Price Performance

Historical Comparison
XGN
LEXX

About XGN Exagen Inc.

Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.

About LEXX Lexaria Bioscience Corp.

Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.

Share on Social Networks: